Back

ROR1 is a novel putative druggable target for diffuse glioma

Ford, C.; John, M.; Rao, P.; Noor, H.

2021-12-05 oncology
10.1101/2021.12.03.21267166 medRxiv
Show abstract

The cell surface receptor ROR1 is a therapeutic target of growing interest in oncology; however, its role in glioma has not been established thus far. This study analyzed associations between ROR1 mRNA expression and clinical outcomes, and histological and molecular subtypes in four independent glioma (grades II-IV) transcriptomic datasets (The Cancer Genome Atlas-GBMLGG, Chinese Glioma Genome Atlas, Repository for Molecular Brain Neoplasia, and GSE16011), encompassing a total of 2,388 cases. The data strongly suggests that ROR1 may be associated with poorer outcomes and more aggressive disease. Taken together, ROR1 should be further examined as a novel putative druggable target for glioma, a cancer that currently has very limited therapeutic options.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.